Caris Life Sciences
Delivers tissue and blood molecular profiling for oncology care and biopharma research.
Something off on this page? Send us feedback.
Profile
Combines tissue and blood molecular profiling with sequencing, AI/ML, and a clinico-genomic dataset. MI Profile and Caris Assure serve clinical oncology, while biopharma clients use testing, data and bioinformatics, and discovery services.
MI Profile provides tissue-based molecular profiling, while Caris Assure provides blood-based profiling for oncology. Sequencing, AI/ML, and a clinico-genomic dataset sit behind the platform’s clinical molecular-profiling services.
Biopharma clients use Caris for testing, data and bioinformatics, and discovery work. Operations extend from Irving to locations in Phoenix, New York, Cambridge, Basel, and Tokyo, connecting a clinical portfolio with biopharma services.
Founded in 2008 through the acquisition of Molecular Profiling Institute, the business remains founder-led by David Dean Halbert. Its precision-medicine platform combines molecular information with AI/ML for oncology-focused clinical and biopharma use.
Company facts
Categories
Key statistics
Year to date −5.0% · Average volume (30d) 5.1M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 7, 2026 | BTIG | Reiterate | Buy | $32 | $33 |
| Aug 6, 2026 | Evercore ISI | Reiterate | Outperform | $25 | $26 |
| Jul 6, 2026 | Evercore ISI | Target | $38 | $25 | |
| May 8, 2026 | Robert W. Baird | Target | $26 | $22 | |
| May 8, 2026 | BTIG | Reiterate | Buy | $45 | $32 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.01 | $0.00 | −139.2% | $238.1M | $263.7M | +10.8% | +21.58% |
| May 7, 2026Q1 FY26 | −$0.02 | $0.00 | +92.5% | $209.4M | $216.2M | +3.2% | −18.60% |
| Feb 26, 2026Q4 FY25 | −$0.02 | $0.28 | +1,500.0% | $240.4M | $292.9M | +21.8% | +4.68% |
| Nov 5, 2025Q3 FY25 | −$0.08 | $0.08 | +200.0% | $280.9M | $216.8M | −22.8% | −15.75% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $120.9M | $181.4M | $216.8M | $292.9M | $216.2M | $263.7M | |
| Gross profit | $57.1M | $113.7M | $147.5M | $220.9M | $141.3M | $179.6M | |
| Operating income | −$58.0M | $18.0M | $32.6M | $88.4M | $5.3M | $26.9M | |
| Net income | −$102.6M | −$71.8M | $24.3M | $82.0M | −$510.0K | −$637.0K | |
| Diluted EPS | −$0.40 | −$1.87 | $0.08 | $0.28 | −$0.00 | −$0.00 | |
| Gross margin | 47.2% | 62.7% | 68.0% | 75.4% | 65.4% | 68.1% | |
| Operating margin | -47.9% | 9.9% | 15.1% | 30.2% | 2.4% | 10.2% |
Fiscal years (4-quarter sums)FY18 $432.1M · FY19 $424.4M · FY20 $324.1M · FY24 $412.3M · FY25 $812.0M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $793.1M · Total debt $452.4M · Total assets $1.23B · Shareholders' equity $591.7M
Dividends
No dividends on record.
Ownership
Institutions and insiders are filed separately and overlap, so together they can pass the whole company. No split is drawn from them.
Shares outstanding 282.68M · Float 11.29M · 4.0% free float
A Form 4 total here can count shares the filer formally disclaims — an award voted by proxy, for instance — which the holder's own Schedule 13D/G excludes, so where the two disagree the schedule's smaller figure is used.
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| David D. Halbert · director, 10 percent owner, officer: See Remarks | 123.60M | 43.72% | Form 4 | May 18, 2026 |
| FMR LLC | 30.92M | 10.94% | 13F | Aug 13, 2026 |
| TSSP Sub-Fund HoldCo, LLC | 23.17M | 8.30% | 13G | Jul 28, 2025 |
| J H Whitney VI L P | 18.26M | 6.50% | 13G | May 12, 2026 |
| ADAPT I Ltd. · 10 percent owner | 16.94M | 5.99% | Form 4 | Jun 23, 2025 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 15, 2026 | Jon Halbert | director | +68,000 | $14.56 |
| May 11, 2026 | Jeff L. Vacirca | director | +31,050 | $16.15 |
| Dec 11, 2025 | Luke Thomas Power | officer: See Remarks | −62,250 | $26.58 |
| Nov 7, 2025 | David Baxley Spetzler | officer: President | +400 | $23.85 |
| Nov 7, 2025 | John Russel Denton | officer: See Remarks | +4,184 | $24.09 |
Peers
- Tempus AI
Genomic profiling, liquid biopsy, MRD, and AI/data services
- Guardant Health
Blood-based oncology profiling, monitoring, screening, and biopharma data
- Natera
ctDNA MRD testing and precision-medicine diagnostics
- GRAIL
Multi-cancer early detection from a blood draw
- NeoGenomics
Oncology diagnostics spanning NGS profiling, liquid biopsy, and MRD
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Caris Life Sciences | $25.63 | −0.03% | $7.25B | 71.6 | 101.6 | 7.3 | +45.4% |
| Tempus AI | $63.44 | −0.89% | $11.22B | — | — | 7.8 | +21.6% |
| Guardant Health | $161.50 | −0.03% | $21.67B | — | — | 18.3 | +44.3% |
| Natera | $325.30 | −0.26% | $46.73B | — | — | 17.3 | +37.7% |
| GRAIL | $80.00 | −0.01% | $3.43B | — | — | 20.8 | +25.7% |
| NeoGenomics | $18.20 | +0.86% | $463.8M | — | 64.9 | 0.6 | +11.2% |
| Median | — | 64.9 | 17.3 | +25.7% |